Report

The India cancer biomarkers market was valued at USD 1.18 Billion in 2024, driven by increasing prevalence of cancer across the region. The market is anticipated to grow at a CAGR of 6.00% during the forecast period of 2025-2034, with the values likely to reach USD 2.11 Billion by 2034. With high mortality rates in cancers like breast, cervical, and lung due to late diagnosis, there is an increasing demand for biomarker tests that enable early, accurate detection and personalized treatment strategies.

India Cancer Biomarkers Market Overview

According to ICMR-National Institute of Cancer Prevention and Research, India is witnessing a growing cancer burden, with approximately 2.5 million people currently living with the disease. Each year, over 7 lakh new cancer cases are registered, and around 5.56 lakh cancer-related deaths are reported. The large and growing cancer-affected population creates a significant demand for advanced diagnostic tools. Biomarker-based tests enable early detection, risk assessment, and personalized treatment, which are crucial in improving patient outcomes. Given these factors, the cancer biomarkers market in India is poised for significant growth in the forecast period.

India Cancer Biomarkers Market Growth Drivers

Rise in Government Initiatives to Boost Market Growth

With a strong focus on prevention, early detection, treatment, and innovation, Indian government's is coming up with comprehensive strategies to combat cancer. A press release titled "Towards a Cancer-Free India" revealed that in the Union Budget 2025-26, INR 99,858.56 crore has been allocated to the Ministry of Health and Family Welfare, including INR 3,900.69 crore dedicated specifically to health research. This substantial investment is set to boost cancer diagnostics research, particularly in biomarker discovery and validation, which will drive growth in the cancer biomarkers market. Additionally, the government plans to establish Day Care Cancer Centres in every district hospital, with 200 centers targeted for launch in 2025-26. This move aims to decentralize cancer treatment and improve access to diagnostic services, thereby increasing demand for reliable, efficient biomarker-based testing solutions.

India Cancer Biomarkers Market Trends

Some of the notable market trends include an emphasis on early diagnosis and personalized treatment to improve patient outcomes and reshape the landscape of cancer diagnostics in the country.

Product Launches to Drive Market Growth

A key trend shaping the market is the accelerated pace of new product launches, such as indigenously developed diagnostic kits aimed at early detection of cancers. In September 2024, Agappe Diagnostics Ltd. and Japan's Fujirebio Holdings Inc., collaborated to launch indigenous diagnostic kits for early detection of cancer, Alzheimer's, and gastrointestinal disorders under the 'Make in India' initiative. These kits utilize Chemiluminescent Enzyme Immunoassay (CLEIA) technology, enhancing the precision of early disease detection. Manufactured in Kochi, Kerala, and approved by the Drugs Controller General of India, these kits are set to be available in laboratories nationwide by the end of the month. This development not only reduces dependency on imports but also aligns with India's goal of self-reliance in healthcare technologies.

India Cancer Biomarkers Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product

- Instruments
??- Imaging Instruments
??- Pathology-based Instruments
??- Biopsy Instruments

- Consumables
??- Antibodies
??- Kits & Reagents
??- Probes

- Bioinformatics Software

Market Breakup by Biomarker

- Epigenetic Biomarkers
- Metabolic Biomarkers
- Genetic Biomarkers
- Proteomic Biomarkers
- Others

Market Breakup by Types of Cancer

- Breast cancer
- Cervical cancer
- Lung cancer
- Prostate cancer
- Colorectal cancer
- Liver cancer
- Others

Market Breakup by Technology

- OMIICS Technologies
??- Proteomics
??- Genomics
??- Others

- Imaging Technologies

??- Ultrasound Imaging
??- Computed Tomography
??- Magnetic Resonance Imaging
??- Positron Emission Tomography
??- Mammography

Market Breakup by Application

- Diagnostics
- Drug Discovery and Development
- Personalized medicine
- Others

Market Breakup by End User

- Hospitals
- Academic and Research Centers
- Diagnostic Laboratories
- Pharmaceutical Companies
- Others

Market Breakup by Region

- North India
- East and Central India
- West India
- South India

India Cancer Biomarkers Market Share

Breast Cancer and Lung Cancer Hold a Substantial Share Based on Segmentation by Type of Cancer

The cancer biomarkers market in India is primarily driven by the high prevalence and mortality rates of specific cancers, with breast, cervical, lung, and oral cancers accounting for the majority of the disease burden. Breast and cervical cancers dominate among women, with one woman dying of cervical cancer every eight minutes and a 50% mortality rate among newly diagnosed breast cancer cases.

In men, lung and oral cavity cancers are among the leading causes of death, largely due to tobacco use, which causes around 2,500 deaths daily. Lung cancer alone accounts for one in five male deaths. These statistics underscore a strong demand for biomarkers for early detection, diagnosis, and personalized treatment, particularly in breast, cervical, and lung cancers.

India Cancer Biomarkers Market Analysis by Region

The market shows significant regional variation, with the highest growth seen in South and West India due to better healthcare infrastructure, higher awareness, and concentration of advanced diagnostic centers in cities like Bangalore, Chennai, Mumbai, and Pune. South India leads in the adoption of biomarker-based diagnostics, especially for breast and cervical cancers, supported by strong medical research and private healthcare investment. North India, including Delhi NCR and parts of Punjab and Uttar Pradesh, also shows high market potential due to rising cases of lung and oral cancers linked to pollution and tobacco use.

Leading Players in the India Cancer Biomarkers Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd., headquartered in Basel, Switzerland, was established in 1896. A global leader in pharmaceuticals and diagnostics, Roche plays a significant role in India's biomarker market through its subsidiary Roche Diagnostics India. The company offers cutting-edge solutions in oncology, cardiology, and infectious disease biomarkers. With a strong emphasis on personalized healthcare, Roche supports early detection and disease monitoring, enhancing clinical outcomes and research across Indian healthcare institutions and laboratories.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc., based in Waltham, Massachusetts, USA, was founded in 2006. It is a major player in India's biomarker landscape, offering a wide array of analytical instruments, reagents, and assay technologies. The company supports biomarker discovery and validation in oncology, neurology, and immunology. Through its India operations, Thermo Fisher collaborates with academic, clinical, and pharmaceutical partners to accelerate precision medicine, enabling high-throughput biomarker analysis and molecular diagnostics across the country.

Abbott Laboratories Inc.

Headquartered in Abbott Park, Illinois, USA, Abbott Laboratories was founded in 1888. In India, Abbott is a prominent contributor to the biomarker market through its diagnostics division. The company delivers innovative biomarker-based tests and platforms, particularly in cardiology, infectious diseases, and diabetes management. With robust R&D and local collaborations, Abbott helps enhance diagnostic accuracy and timely treatment, strengthening India's healthcare ecosystem with reliable biomarker-driven insights and expanding access to advanced diagnostic solutions.

Illumina, Inc.

Illumina, Inc., founded in 1998 and headquartered in San Diego, California, is a global leader in genomics. In India, Illumina plays a pivotal role in advancing the biomarker market through its next-generation sequencing (NGS) technologies. These platforms are instrumental in biomarker discovery, especially in oncology and rare genetic disorders. Illumina partners with research institutions and diagnostic labs across India to enable precision medicine, driving innovations in genetic screening, disease prediction, and personalized treatment strategies.

Other players in the market include QIAGEN N.V., PerkinElmer Inc., Bio-Rad Laboratories, Inc., and Agilent Technologies, Inc., among others.

Key Questions Answered in the India Cancer Biomarkers Market Report

- What was the India cancer biomarkers market value in 2024?
- What is the India cancer biomarkers market forecast outlook for 2025-2034?
- What are the major factors aiding the India cancer biomarkers market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major India cancer biomarkers market trends?
- Which product is expected to dominate the market segment?
- Which biomarker is projected to lead the market segment?
- Which type of cancer is expected to dominate the market segment?
- Which application is expected to lead the market segment?
- Which product is expected to dominate the market segment?
- Who are the key players involved in the India cancer biomarkers market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?